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The second sentence of the Central Illustration legend was inadvertently omitted. The full image and corrected
legend are printed below.
The authors apologize for this error.+ 
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CENTRAL ILLUSTRATION Clinical Testing and Management Strategies in HCM
*Patients without LV outﬂow tract gradient (<30 mm Hg) at rest should also undergo stress (exercise) echocardiography. Not shown here, on
initial evaluation, all HCM patients undergo sudden death risk stratiﬁcation (refer to Fig. 5). †Generally regarded as $30 mm Hg outﬂow
gradient, but $50 mm Hg when septal reduction intervention is considered (i.e., septal myectomy; alcohol ablation). ‡No or trivial (<30
mmHg) outﬂow gradient at rest andwith exercise. §No data on beneﬁt of pharmacologic therapy, although beta-blockers are often administered
prophylactically in clinical practice. kObstructive: usually, beta-blockers or possibly calcium channel antagonists (verapamil), or disopyramide.
Nonobstructive: beta-blockers, calcium channel antagonists, and possibly diuretics administered judiciously. ¶Screening targets relatives
without clinical evidence of HCM phenotype. #Could differentiate hypertrophic cardiomyopathy (HCM) from other causes of left ventricular
hypertrophy (LVH), including patients with history of systemic hypertension, or highly trained athletes.http://dx.doi.org/10.1016/j.jacc.2014.07.940
